Hussayn Alrayes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hussayn Alrayes has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Georgi Fram
2 shared publications- James Lee
Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan, USA
2 shared publications Mir Basir
Department of Cardiovascular Medicine, Henry Ford Health Systems, Detroit, Michigan
2 shared publicationsPedro Villablanca
Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan, USA
2 shared publicationsTiberio Frisoli
Center for Structural Heart Disease, Henry Ford Health System, Detroit, Michigan, USA
2 shared publicationsAhmad Alkhatib
Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas
1 shared publication
Latest Publications
- Open Access
- 26 February 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (8) , 103237
Impromptu SVC Caval Implantation During Tricuspid Transcatheter Valve-in-Ring
- 26 February 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (8) , 103237
Open AccessImpromptu SVC Caval Implantation During Tricuspid Transcatheter Valve-in-Ring
- 1 January 2025
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Safety and Complications Associated With the Use of Protamine in Percutaneous Coronary Intervention
There is a paucity of data on the use of protamine after PCI. The purpose of this study was to assess the incidence of thrombotic complications of protamine after high-risk PCI. The authors conducted a retrospective analysis of 168 patients. All patients received protamine intra- or immediately post-index PCI. Baseline characteristics and procedural characteristics including heparin dosing, protamine dosing, and bleeding and thrombotic complications were evaluated. The primary outcome was the incidence of acute stent thrombosis (ST), subacute ST, and 'other' thrombotic complications. Secondary outcomes included mortality within 24 hours and within 30 days of the index procedure. A total of 168 patients were included. The majority of patients received dual anti-platelet therapy prior to the index procedure (85%). The average procedure time was 202 ± 103 minutes, and an average of 2.59 (± 1.38) stents were deployed. An average protamine dose of 32mg was administered, and the median dose was 20mg (IQR 20). Seventy-three (43%) had a coronary perforation and five (3%) had access site related bleeding requiring transfusion. Four (2%) patients had acute ST, no patients experienced subacute ST, and 2 (1%) patients developed non-coronary arterial thrombosis. Eight (5%) died within 24 hours of their PCI and 14 (8%) patients died within 30 days after PCI. In our cohort, administration of protamine was well tolerated in the majority of patients, however, 3.6% of patients did experience coronary or peripheral arterial thrombosis warranting caution when using protamine in these challenging scenarios.
- 1 January 2025
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
Safety and Complications Associated With the Use of Protamine in Percutaneous Coronary Intervention
There is a paucity of data on the use of protamine after PCI. The purpose of this study was to assess the incidence of thrombotic complications of protamine after high-risk PCI. The authors conducted a retrospective analysis of 168 patients. All patients received protamine intra- or immediately post-index PCI. Baseline characteristics and procedural characteristics including heparin dosing, protamine dosing, and bleeding and thrombotic complications were evaluated. The primary outcome was the incidence of acute stent thrombosis (ST), subacute ST, and 'other' thrombotic complications. Secondary outcomes included mortality within 24 hours and within 30 days of the index procedure. A total of 168 patients were included. The majority of patients received dual anti-platelet therapy prior to the index procedure (85%). The average procedure time was 202 ± 103 minutes, and an average of 2.59 (± 1.38) stents were deployed. An average protamine dose of 32mg was administered, and the median dose was 20mg (IQR 20). Seventy-three (43%) had a coronary perforation and five (3%) had access site related bleeding requiring transfusion. Four (2%) patients had acute ST, no patients experienced subacute ST, and 2 (1%) patients developed non-coronary arterial thrombosis. Eight (5%) died within 24 hours of their PCI and 14 (8%) patients died within 30 days after PCI. In our cohort, administration of protamine was well tolerated in the majority of patients, however, 3.6% of patients did experience coronary or peripheral arterial thrombosis warranting caution when using protamine in these challenging scenarios.
- 1 January 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (1) , E69-E70
Failed Manta Closure Device After High-Risk PCI
This set of Clinical Images demonstrates that while the collagen-based Manta closure device (Teleflex) is a safe and effective option to close large-bore arterial access sites, complications can occur in at-risk cohorts, as seen in this clinical scenario.
- 1 January 2022
- Published by HMP Communications, LLC in Journal of Invasive Cardiology
- Vol. 34 (1) , E69-E70
Failed Manta Closure Device After High-Risk PCI
This set of Clinical Images demonstrates that while the collagen-based Manta closure device (Teleflex) is a safe and effective option to close large-bore arterial access sites, complications can occur in at-risk cohorts, as seen in this clinical scenario.
- Open Access
- 2 November 2021
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 15
Current Landscape of Temporary Percutaneous Mechanical Circulatory Support Technology
Mechanical circulatory support devices provide hemodynamic support to patients who present with cardiogenic shock. These devices work using different mechanisms to provide univentricular or biventricular support. There is a growing body of evidence supporting use of these devices as a goal for cardiac recovery or as a bridge to definitive therapy, but definitive, well-powered studies are still needed. Mechanical circulatory support devices are increasingly used using shock team and protocols, which can help clinicians in decision making, balancing operator and institutional experience and expertise. The aim of this article is to review commercially available mechanical circulatory support devices, their profiles and mechanisms of action, and the evidence available regarding their use.
- 2 November 2021
- Published by Radcliffe Medical Media Ltd in US Cardiology Review
- Vol. 15
Open AccessCurrent Landscape of Temporary Percutaneous Mechanical Circulatory Support Technology
Mechanical circulatory support devices provide hemodynamic support to patients who present with cardiogenic shock. These devices work using different mechanisms to provide univentricular or biventricular support. There is a growing body of evidence supporting use of these devices as a goal for cardiac recovery or as a bridge to definitive therapy, but definitive, well-powered studies are still needed. Mechanical circulatory support devices are increasingly used using shock team and protocols, which can help clinicians in decision making, balancing operator and institutional experience and expertise. The aim of this article is to review commercially available mechanical circulatory support devices, their profiles and mechanisms of action, and the evidence available regarding their use.